Amplified Sciences started patient enrollment for PanAMP, a multicenter real-world clinical utility study assessing how its PanCystPro assay influences clinical decision-making for early pancreatic cancer. The company plans to evaluate whether assay outputs change downstream management in routine practice. The study design targets the translation gap between analytic performance and measurable care pathways. Amplified Sciences is using the real-world framework to examine whether the test can reduce uncertainty for clinicians and improve consistency in how suspicious pancreatic findings are handled. Enrollment begins as the broader pancreatic diagnostics market accelerates around earlier-stage detection tools.